A practical reference on Angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Vacutainer tubes may contain additional substances that preserve blood for processing in a medical laboratory. Using the wrong tube may make the blood sample unusable for the intended purpose. These additives are typically thin film coatings applied using an ultrasonic nozzle. The additives may include anticoagulants (EDTA, sodium citrate, heparin) or a gel with density between those of blood cells and blood plasma. Additionally, some tubes contain additives that preserve certain components of or substances within the blood, such as glucose. When a tube is centrifuged, the materials within are separated by density, with the blood cells sinking to the bottom and the plasma or serum accumulating at the top. Tubes containing gel can be easily handled and transported after centrifugation without the blood cells and serum mixing.
== Further reading == López-Alonso, JP; Diez-Garcia, F; Font, J; Ribó, M; Vilanova, M; Scholtz, JM; González, C; Vottariello, F; Gotte, G; Libonati, M; Laurents, DV (2009). "Carbodiimide EDC Induces Cross-Links That Stabilize RNase A C-dimer against Dissociation: EDC Adducts Can Affect Protein Net Charge, Conformation and Activity". Bioconjugate Chemistry. 20 (8): 1459–1473. doi:10.1021/bc9001486. PMID 19606852. Nakajima, N; Ikada, Y (1995). "Mechanism of Amide Formation by Carbodiimide for Bioconjugation in Aqueous Media". Bioconjugate Chemistry. 6 (1): 123–130. doi:10.1021/bc00031a015. PMID 7711098.
Ethanol is classified as a teratogen—a substance known to cause birth defects; according to the U.S. Centers for Disease Control and Prevention (CDC), alcohol consumption by women who are not using birth control increases the risk of fetal alcohol spectrum disorders (FASDs). This group of conditions encompasses fetal alcohol syndrome, partial fetal alcohol syndrome, alcohol-related neurodevelopmental disorder, static encephalopathy, and alcohol-related birth defects. The CDC currently recommends complete abstinence from alcoholic beverages for women of child-bearing age who are pregnant or trying to become pregnant.
Peukert argued that societies that have reached "classical modernity" are characterized by advanced capitalist economic organization and mass production, by the "rationalization" of culture and society, massive bureaucratization of society, the "spirit of science" assuming a dominant role in popular discourses, and the "social disciplining" and "normalization" of the majority of ordinary people. Peukert was greatly influenced by the theories of Max Weber, but unlike many other scholars, who saw Weber attempting to rebut Karl Marx, he viewed Weber's principal intellectual opponent as Friedrich Nietzsche. Peukert wrote that for Weber, the principal problems of modern Germany were: The increasing "rationalization" of everyday life via bureaucratization and secularism had led to a "complete demystification of the world". The popularity of the "spirit of science" had led to a misguided belief that science could solve all problems within the near-future. Contrary to the "Bielefeld School", Peukert argued by the time of the Weimar Republic, Germany had broken decisively with the past, and had become a thoroughly "modern" society in all its aspects. Peukert argued that the very success of German modernization inspired by the "dream of reason" meant the contradictions and problems of "classical modernity" were felt more acutely in Germany than elsewhere. For Peukert, the problems of "classical modernity" were:
Their vows make everyone forget the "dire situation" for a moment, until Ari suddenly collapses. Ari succumbs to the cancer and his death aired on 7 March 2022. After the episode was broadcast aired, Kipa-Williams took to his Instagram account to post a thank you message to the show's cast, crew, and fans for their support. He said "This Iconic Ozzie TV show took risks. I'm honoured to have co-created Māori cultural storylines, and will forever be proud of those scenes that made it to screen.. it was true teamwork.. My hope is this opens the door for more diversity. Thank you for everything Ariki Wiremu Parata, you taught me a lot. I'm gonna miss you." The character made one final appearance on 15 March 2022, as Ari appears to Mia in a dream. The following year, Kipa-Williams revealed that he quit Home and Away because of "a calling" to the Māori culture. He moved back to Aotearoa, where he bought a farm and began lessons in te reo in order to become more fluent in the language.
Sources: en.wikipedia.org
Numerous protesters asked for a civilian government. On Saturday 13 April 2019, al-Burhan announced that a civilian government would soon be established. Al-Burhan promised that the transitional period would take a maximum of two years. Negotiations started to take place with the opposition leaders to achieve this.
=== Singles and music videos === Let God Sort Em Out's lead single "Ace Trumpets" was released on May 30, 2025. The song garnered media attention for lyrics that reference Pusha T's former boss and long-standing creative partner West, interpreted by some as being dismissive of West's public outbursts. "Ace Trumpets", with its "icy drums, lush synths, and unsettling elegance", received positive reviews from music critics. Alex Hudson of Exclaim! commented: "The beat certainly isn't Pharrell's hookiest, but the thundering 808 bludgeons with pure muscle. Hell yeah—welcome back, guys." Tom Breihan of Stereogum wrote: "Pusha and Malice both sound cold and imperious. Malice's verse is a real masterclass." Dash Lewis of Pitchfork called the song "a menacing return to form for the coke rap auteurs. Pharrell Williams' beat, with its rimshot snare, chest-caving bass, and synth drone that sounds like a screwed-down tornado siren, conveys the same creeping tension he supplied Pusha with for 2022's It's Almost Dry." A lyric video was released on June 4. Described by publications as the second single, promotional single "So Be It" was released exclusively as a black-and-white Hannan Hussain-directed music video via YouTube and Instagram on June 17, depicting Clipse in a mansion with various classic luxury cars on the property. Some fans and journalists mistakenly thought the song was a diss toward West based on previewed lyrics. "So Be It" was well received by critics. Zachary Horvath of HotNewHipHop wrote that "potential dissing aside, the music is great on its own.
Amyloidosis has a combined estimated prevalence of 30 per 100,000 persons with the three most common forms being AL, ATTR, and AA. The median age at diagnosis is 64. AL has the highest incidence at approximately 12 cases per million persons per year and an estimated prevalence of 30,000 to 45,000 cases in the US and European Union. AA amyloidoses is the most common form in developing countries and can complicate longstanding infections with tuberculosis, osteomyelitis, and bronchiectasis. AA amyloidosis is caused by an increase in extracellular deposition of serum amyloid A (SAA) protein. SAA protein levels can rise in both direct and indirect manners, through infection, inflammation, and malignancies. The most common causes of AA amyloidosis in the West are rheumatoid arthritis, inflammatory bowel disease, psoriasis, and familial Mediterranean fever. People undergoing long-term hemodialysis (14–15 years) can develop amyloidosis from accumulation of light chains of the HLA 1 complex which is normally filtered out by the kidneys. Wild-type transthyretin (ATTR) amyloidosis is found in a quarter of elderly at postmortem. ATTR is found in 13–19% of people experiencing heart failure with preserved ejection fraction, making it a very common form of systemic amyloidosis.
Caesium (55Cs) has 41 known isotopes, ranging in mass number from 112 to 152. Only one isotope, 133Cs, is stable. The longest-lived radioisotopes are 135Cs with a half-life of 1.33 million years, 137Cs with a half-life of 30.04 years and 134Cs with a half-life of 2.0650 years. All other isotopes have half-lives less than 2 weeks, most under an hour. Caesium is an abundant fission product (135 and 137 are directly produced) and various isotopes are of concern as such, see the sections below. Beginning in 1945 with the commencement of nuclear testing, caesium radioisotopes were released into the atmosphere, where caesium is absorbed readily into solution and is returned to the surface of the Earth as a component of radioactive fallout. Once caesium enters the ground water, it is deposited on soil surfaces and removed from the landscape primarily by particle transport. As a result, the input function of these isotopes can be estimated as a function of time.
As a medication, insulin is any pharmaceutical preparation of the protein hormone insulin that is used to treat high blood glucose. Such conditions include type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. Insulin is also used along with glucose to treat hyperkalemia (high blood potassium levels). Typically it is given by injection under the skin, but some forms may also be used by injection into a vein or muscle. There are various types of insulin, suitable for various time spans. The types are often all called insulin in the broad sense, although in a more precise sense, insulin is identical to the naturally occurring molecule whereas insulin analogues have slightly different molecules that allow for modified time of action. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 157th most commonly prescribed medication in the United States, with more than 3 million prescriptions. Insulin can be made from the pancreas of pigs or cows. Human versions can be made either by modifying pig versions, or recombinant technology using mainly E. coli or Saccharomyces cerevisiae. It comes in three main types: short–acting (such as regular insulin), intermediate-acting (such as neutral protamine Hagedorn (NPH) insulin), and longer-acting (such as insulin glargine).
Sources: en.wikipedia.org
Although there is a theoretical yield of 38 ATP molecules per glucose during cellular respiration, such conditions are generally not realized because of losses such as the cost of moving pyruvate (from glycolysis), phosphate, and ADP (substrates for ATP synthesis) into the mitochondria. All are actively transported using carriers that utilize the stored energy in the proton electrochemical gradient.
== Professional affiliations == Beavis was a founding member of Genome Prairie and one of the founders of ProteoMetrics, LLC. He has held academic positions at Rockefeller University, Memorial University of Newfoundland and Labrador, New York University Medical Center, the University of British Columbia and the University of Manitoba. He served on the Editorial Advisory Boards of the Journal of Proteome Research and Rapid Communications in Mass Spectrometry. He has also served on the Editorial Board of Molecular & Cellular Proteomics and on the Editorial Board of Scientific Data. He was part of the Human Proteome Project and a founding member of the U.S. Chromosome 17 project. He has frequently collaborated with David Fenyő on informatics projects.
== Debate over insects' capacity for welfare == Scientists remain uncertain about the existence and degree of pain in invertebrates, including insects. However, a recent review of the neurobiological and behavioral evidence consistent with the hypothesis of pain found strong evidence consistent with precautionary treatment in at least two orders of insects at the adult life stage (Blattodea and Diptera), ultimately considering evidence from over 350 studies. This may explain why 67% of surveyed animal behavior researchers ascribed emotions (of which pain is one), to some, most, nearly all or all insects and why 82% of surveyed entomologists stated they cared about insect welfare due to the intrinsic value of the animal. Both the 2012 Cambridge Declaration on Consciousness, and the 2024 New York Declaration on Animal Consciousness, suggest that there is a realistic possibility of insect consciousness; the New York Declaration signed by many animal ethicists, welfare scientists, neuroscientists, entomologists, and consciousness researchers. As a result of the growing evidence base supporting the plausibility of insect pain and sentience, insect welfare is being increasingly discussed in all settings where insects are used and managed, including laboratory settings. Vincent Wigglesworth suggested a precautionary approach of anaesthetizing insects during potentially painful procedures. John Cooper has written about techniques for "Anesthesia, analgesia, and euthanasia of invertebrates" including insects. Neil A. C.
Insulin-like growth factor-binding protein 3, also known as IGFBP-3, is a protein that in humans is encoded by the IGFBP3 gene. IGFBP-3 is one of six IGF binding proteins (IGFBP-1 to IGFBP-6) that have highly conserved structures and bind the insulin-like growth factors IGF-1 and IGF-2 with high affinity. IGFBP-7, sometimes included in this family, shares neither the conserved structural features nor the high IGF affinity. Instead, IGFBP-7 binds IGF1R, which blocks IGF-1 and IGF-2 binding, resulting in apoptosis.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.